StageBio supports neurologic drug and device development with specialized CNS and PNS pathology expertise, GLP-compliant reporting, and proactive scientific collaboration. Our team of board-certified pathologists, specialized in neuropathology, brings deep experience across neurotoxicity and neurodegeneration, delivering data and interpretation that is accurate, consistent, and built to withstand regulatory scrutiny. From early discovery through IND-enabling programs, we're committed to protecting your timelines and providing you with the confidence to move forward.
For over 15+ years, StageBio has advanced neurologic research through industry-recognized neuropathology expertise backed by a dedicated collaborative team of board-certified pathologists with deep specialization across CNS and PNS indications. We support 200+ GLP and non-GLP neuropathology studies every year, spanning therapies under development to treat Alzheimer's, Parkinson's, ALS, multiple sclerosis, and beyond, delivering the integrated services and regulatory-ready reporting your programs demand. Our neuropathology-trained team doesn’t just read slides; we work as an extension of your team, combining expert evaluation with strategic insight to help you make confident decisions, protect your timelines, and reach IND with clarity.
bringing breadth and depth that accelerates turnaround times and strengthens regulatory confidence
delivering expert CNS and PNS interpretation, validated endpoints, and the regulatory credibility you need to drive programs forward
delivering expert CNS and PNS interpretation, validated endpoints, and the regulatory-grade credibility you need to drive programs forward
We offer comprehensive, GLP-compliant neuropathology services to support your neurologic programs from early preclinical studies through regulatory submission. Backed by 15+ years of experience and a track record of 200+ studies per year across diverse CNS and PNS indications, we deliver the scientific precision, robust endpoints, and on-time reporting your programs require. Our team provides bespoke solutions tailored to your specific therapeutic area and modality, integrating optimized tissue handling, advanced IHC, expert pathology evaluations, and quantitative digital pathology to give you clear safety insight, reliable data, and regulatory confidence at every stage.
Multi-Modality Support: ASO, AAV, LNP, Antibodies, Small Molecules, NMDA Antagonists, & Medical Devices
Direct CNS Delivery: Intracerebroventricular, Intraparenchymal, & Intrathecal delivery with precise evaluation of injection sites, local inflammation, and biodistribution
Perfusion Fixation, Brain & Spinal Cord Trimming
Nerve & Ganglia Dissection
Osmicated Resin Embedding
Developmental Neurotoxicity
Special Stains and Immunolabels, including IBA-1, GFAB, FJB, Bielschowsky Silver, & Luxol Fast Blue
Validated Panels Aligned to Mechanism & Regulatory Expectations
Neurons: NeuN, MAP2
Gliosis & neuroinflammation: GFAP, IBA-1
Myelination: MBP, Luxol Fast Blue
Quantitative Morphometry & Stereology
Workflows delivering reproducible, quantitative endpoints
Digital & High-Throughput Imaging
Whole-slide Scanning: Brightfield & Multiplex Fluorescence
Micro-CT
Image Analysis (Visiopharm)
Remote Access & Integrated Data Management
Meet with our neuropathology team to discuss how StageBio's expert support can protect your timelines, strengthen your regulatory strategy, and deliver the trusted data you need, when you need it.
I have evaluated thousands of slides that StageBio has prepared. Their consistency from slide to slide is remarkable. It makes my job as a pathologist much easier when we contract our work to StageBio! Director of Pathology, Contract Research Organization
We’ve built a trusted relationship with their neuropathology group, allowing us to confidently deliver high-quality neuro insights that stand up to regulatory scrutiny. Vice President, Preclinical Services, Contract Research Organization
Partnering with their molecular team to validate an antibody for our marker of interest gave us critical insight into our neuro program and strengthened decision-making across our development strategy. Director, Nonclinical Development
513.204.4400
